logo

CELERA COR(NSDQ:CRA)
Applera Corporation consists of two operating groups. Celera is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers as well as other known markers. Celera maintains a strategic alliance with Abbott for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera is also discovering and validating therapeutic targets, and it is seeking strategic partnerships to develop therapeutic products based on these discovered targets.
# Employees: 554
Address: 1401 Harbor Bay Parkway,Alameda,CA,USA
Phone: 510-749-4200
Fax: 510-749-4200
Website: www.celera.com
Email: webmaster@celera.com
Sector: Medical
Industry: MED-BIOMED/GENE
Executive Officers
Kathy Ordo??ez (C.E.O.; Dir.)
Joel R. Jung (C.F.O.)
Richard H. Ayers (Dir.)
William G. Green (Dir.)
Peter Barton Hutt (Dir.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 2/16/2010
Mean EPS (Next Qtr): ($0.04)
Mean EPS (Year): ($0.27)
Mean Estimate(Long Term): $15.00
P/E Ratio(Based on EPS estimate): -0.010
Number of Estimates: 9
Shares Performance
Period CRA Compare to S&P
YTD -43.85 % -53.53 %
4 Weeks 0.97 % -0.12 %
12 Weeks -4.58 % -10.04 %
Shares Information
Analyst Coverage: Y
Avg Volume: 589995
Shares Outstanding: 81M
Market Cap: $0.51B
52 Week High: $11.54
52 Week Low: $5.18
P/E Ratio: 22.320
PEG Ratio: -0.010
Split: On 2/22/2000 CRA split by factor of 2.000
Earnings Performance
EPS Growth in Last Quarter: -100.00 %
EPS Growth in Last Year: -100.00 %
Sales Growth in Last Quarter: -3.38 %
Sales Growth in Last Quarter: -12.66 %
Financials
Qtr Book Value: $0.87
Cash Flow/Share: ($0.01)
Change in Payout Ratio: 0.000
Price/Sales: 2.930
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia